Lava Therapeutics Nv Expected To Post A Loss Of 81 Cents A Share: Earnings Preview

LAVA Therapeutics NV

16/05/2022 13:51

* LAVA Therapeutics NV  LVTX.OQ   LVTX.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 18
(estimated). 
    * The Utrecht-based  company is expected to report  a
44.7% decrease in revenue to €509 thousand from €920.63 thousand
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for LAVA Therapeutics
NV is
for a loss of 81 cents per share. For the same quarter last
year, the company reported a loss of €10.19 per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for LAVA
Therapeutics
NV is $23​, above​ its last closing price of $3.97. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in euros). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.37       -0.36      -0.38     Missed  -5.6
 Sep. 30 2021  -0.28       -0.27      -0.23     Beat    13.3
 Jun. 30 2021  -0.23       -0.23      -0.23     Met     -0.8​
 Mar. 31 2021  -0.67       -0.67      -10.19    Missed  -1,432
                                                        .3
 ​​                                                     
                                                        ​
 This summary was machine generated May 16 at 12:51 GMT.  All
figures in euros  unless otherwise stated